Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency.

Witkowska-Sędek E, Rumińska M, Stelmaszczyk-Emmel A, Sobol M, Demkow U, Pyrżak B.

Adv Exp Med Biol. 2018;1116:63-73. doi: 10.1007/5584_2018_274.

PMID:
30284692
2.
3.

Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.

Doumouchtsis K, Perrea D, Doumouchtsis S, Tziamalis M, Poulakou M, Vlachos I, Kostakis A.

Ther Apher Dial. 2009 Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x.

PMID:
19379170
4.
5.

sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.

Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, Tziamalis MP, Tsigris C, Kostaki MA, Perrea DN.

J Endocrinol Invest. 2007 Oct;30(9):762-6.

PMID:
17993768
6.

Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.

Tsentidis C, Gourgiotis D, Kossiva L, Doulgeraki A, Marmarinos A, Galli-Tsinopoulou A, Karavanaki K.

Osteoporos Int. 2016 Apr;27(4):1631-1643. doi: 10.1007/s00198-015-3422-5. Epub 2015 Nov 20.

PMID:
26588909
7.

OPG and sRANKL serum levels and incident hip fracture in postmenopausal Caucasian women in the Women's Health Initiative Observational Study.

LaCroix AZ, Jackson RD, Aragaki A, Kooperberg C, Cauley JA, Chen Z, Leboff MS, Duggan D, Wactawski-Wende J.

Bone. 2013 Oct;56(2):474-81. doi: 10.1016/j.bone.2013.05.018. Epub 2013 Jun 2.

8.

Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.

Wasilewska A, Rybi-Szuminska AA, Zoch-Zwierz W.

J Pediatr Endocrinol Metab. 2009 Dec;22(12):1099-104.

PMID:
20333868
9.

The relationship between alkaline phosphatase and bone alkaline phosphatase activity and the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency.

Witkowska-Sędek E, Stelmaszczyk-Emmel A, Majcher A, Demkow U, Pyrżak B.

Acta Biochim Pol. 2018;65(2):269-275. doi: 10.18388/abp.2017_2541. Epub 2018 Apr 13.

10.

Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.

Todenhöfer T, Hennenlotter J, Leidenberger P, Wald A, Hohneder A, Kühs U, Mischinger J, Aufderklamm S, Gakis G, Blumenstock G, Stenzl A, Schwentner C.

BJU Int. 2014 Jan;113(1):152-9. doi: 10.1111/j.1464-410X.2012.11759.x. Epub 2013 Jan 29.

11.

Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.

Ozkaya O, Buyan N, Bideci A, Gonen S, Ortac E, Fidan K, Cinaz P, Söylemezoğlu O.

Nephron Clin Pract. 2007;105(4):c153-8. Epub 2007 Jan 25.

PMID:
17259742
13.

Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Marek B, Świętochowska E, Kajdaniuk D, Strzelczyk J, Cieślicka A, Wołkowska-Pokrywa K, Kos-Kudła B.

Endokrynol Pol. 2015;66(4):313-21. doi: 10.5603/EP.2015.0040.

14.

Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Kananen K, Volin L, Laitinen K, Ruutu T, Välimäki MJ.

Osteoporos Int. 2006;17(5):724-30. Epub 2005 Dec 31.

PMID:
16437190
15.
16.

Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.

Reyes-García R, Muñoz-Torres M, García DF, Mezquita-Raya P, García Salcedo JA, de Dios Luna J.

Menopause. 2010 Jan-Feb;17(1):140-4. doi: 10.1097/gme.0b013e3181ac0cc1.

PMID:
19574937
17.
18.

Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.

Zhao HY, Liu JM, Ning G, Zhao YJ, Chen Y, Sun LH, Zhang LZ, Xu MY, Chen JL.

Osteoporos Int. 2008 Feb;19(2):221-6. Epub 2007 Aug 17.

PMID:
17703270
19.

RANKL/RANK/OPG system and bone status in females with anorexia nervosa.

Ostrowska Z, Ziora K, Oświęcimska J, Swiętochowska E, Szapska B, Wołkowska-Pokrywa K, Dyduch A.

Bone. 2012 Jan;50(1):156-60. doi: 10.1016/j.bone.2011.09.054. Epub 2011 Oct 6.

PMID:
22001124
20.

The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa.

Ohwada R, Hotta M, Sato K, Shibasaki T, Takano K.

Endocr J. 2007 Dec;54(6):953-9. Epub 2007 Nov 12.

Supplemental Content

Support Center